BACE1 (Beta-Secretase 1)

Migration, Crosslink

📖

BACE1 (Beta-Secretase 1)

active

wiki page Created: 2026-04-02T07:19:32 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-bace1

📖 Wiki Page

gene1535 wordssynced 2026-04-02

BACE1 (Beta-Secretase 1)

| Property | Value |
|----------|-------|
| Gene Symbol | BACE1 |
| Full Name | Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 |
| Chromosomal Location | 11q13.2 |
| NCBI Gene ID | 23626 |
| OMIM ID | 604252 |
| Ensembl ID | ENSG00000186318 |
| UniProt ID | Q15118 |
| Encoded Protein | Beta-secretase 1, Aspartic protease |
| Associated Diseases | Alzheimer's disease, Down syndrome, Schizophrenia |

</div>

Introduction

BACE1 (Beta-Secretase 1, also known as Beta-site [Amyloid Precursor Protein](/genes/app) Cleaving Enzyme 1) is a member of the aspartyl protease family that plays a critical role in the production of [amyloid-beta](/proteins/amyloid-beta) (Aβ) peptides in Alzheimer's disease. BACE1 is the rate-limiting enzyme responsible for the first proteolytic cleavage of the amyloid precursor protein (APP), initiating the amyloidogenic pathway that leads to Aβ generation[@vassar1999][@sinha1999].

Pathway / Mechanism Diagram

...

BACE1 (Beta-Secretase 1)

| Property | Value |
|----------|-------|
| Gene Symbol | BACE1 |
| Full Name | Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 |
| Chromosomal Location | 11q13.2 |
| NCBI Gene ID | 23626 |
| OMIM ID | 604252 |
| Ensembl ID | ENSG00000186318 |
| UniProt ID | Q15118 |
| Encoded Protein | Beta-secretase 1, Aspartic protease |
| Associated Diseases | Alzheimer's disease, Down syndrome, Schizophrenia |

</div>

Introduction

BACE1 (Beta-Secretase 1, also known as Beta-site [Amyloid Precursor Protein](/genes/app) Cleaving Enzyme 1) is a member of the aspartyl protease family that plays a critical role in the production of [amyloid-beta](/proteins/amyloid-beta) (Aβ) peptides in Alzheimer's disease. BACE1 is the rate-limiting enzyme responsible for the first proteolytic cleavage of the amyloid precursor protein (APP), initiating the amyloidogenic pathway that leads to Aβ generation[@vassar1999][@sinha1999].

Pathway / Mechanism Diagram

Mermaid diagram (expand to render)

Overview

BACE1 is a transmembrane aspartyl protease that catalyzes the ectodomain shedding of numerous type I membrane proteins. Its primary substrate is APP, which BACE1 cleaves at the beta-site to generate a soluble APPβ (sAPPβ) fragment and a membrane-bound C-terminal fragment (CTFβ). This cleavage is followed by [γ-secretase](/proteins/gamma-secretase) cleavage of CTFβ, releasing [amyloid-beta](/proteins/amyloid-beta) peptides of varying lengths (Aβ40, Aβ42)[@yan1999].

Beyond APP, BACE1 cleaves numerous other substrates including[@evin2015]:

APP-like proteins (APLP1, APLP2)
Seizure protein 6 (SEZ6)
Close homolog of L1 (CHL1)
Neuregulin 1 (NRG1) - critical for myelination
Voltage-gated sodium channel subunits
LDL receptor-related proteins
GABA(A) receptor subunits - newly discovered mechanism of neural hyperexcitability[@zhang2025]

BACE1 is expressed at high levels in [neurons](/cell-types/neurons), particularly in the hippocampus and [cortex](/brain-regions/cortex), brain regions most affected in Alzheimer's disease. Its activity is highest in the Golgi apparatus and endosomes, compartments where APP processing occurs[@cai2011].

Discovery and History

The discovery of BACE1 represented a major breakthrough in AD research:

1999: BACE1 was simultaneously cloned and characterized by multiple groups
2000-2005: Development of first-generation BACE1 inhibitors
2007-2012: Multiple BACE1 inhibitors entered clinical trials
2013-2018: Several trials failed due to safety concerns
2019-Present: Renewed interest in substrate-selective and partial inhibition approaches[@jacobson2022]

Molecular Biology of BACE1

Protein Structure

BACE1 is a type I transmembrane protein with the following domains:

| Domain | Function | Key Features |
|--------|----------|--------------|
| Signal Peptide | Secretory pathway targeting | Cleaved in ER |
| Prodomain | Enzyme maturation | Autocatalytic cleavage |
| Catalytic Domain | Protease activity | Aspartyl protease motif (DTG) |
| Transmembrane Domain | Membrane anchoring | Single helix |
| Cytoplasmic Domain | Signaling/transport | Contains sorting motifs |

Catalytic Mechanism

BACE1 uses a classic aspartyl protease mechanism:

Pro-BACE1 undergoes autocatalytic cleavage in the secretory pathway

The mature enzyme contains two conserved aspartate residues (DTG motif)

These aspartates act as nucleophiles to hydrolyze peptide bonds

Optimal cleavage site: ^EVKM/D(A/T)↓X^ motif in APP

Function

Normal Physiological Functions

BACE1 participates in several important physiological processes:

APP Processing: Normal cleavage generates sAPPβ with potential neurotrophic properties

Synaptic Function: Regulates synaptic proteins and plasticity

Myelination: Neuregulin-1 cleavage regulates oligodendrocyte function

Neuronal Development: Controls neuronal survival and differentiation

Voltage-gated Channels: Modulates sodium channel function

Role in Alzheimer's Disease Pathogenesis

BACE1 is central to Alzheimer's disease pathogenesis through its role in amyloid-beta production[@may2011]:

| Aspect | Details |
|--------|---------|
| Genetic Evidence | BACE1 expression and activity are elevated in AD brains |
| BACE1 Promoter | Risk variants associated with increased expression |
| Therapeutic Target | Major drug discovery focus for AD modification |
| Knockout Studies | BACE1-/- mice show complete absence of Aβ production |

Disease Associations

Alzheimer's Disease

BACE1 is the rate-limiting enzyme in Aβ production, making it a prime therapeutic target. However, clinical trials have faced significant challenges:

Clinical Trial History:

| Compound | Company | Outcome |
|----------|---------|---------|
| LY2811376 (Eli Lilly) | Terminated | Toxicity |
| LY2886721 (Eli Lilly) | Terminated | Liver toxicity |
| MK-8931/Verubecestat (Merck) | Terminated | Cognitive decline |
| E2609 (Eisai) | Terminated | Safety concerns |
| JNJ-54861911 (Janssen) | Terminated | Safety concerns |

Reasons for Trial Failures:

Mechanism-based toxicity due to essential substrates
Cognitive worsening with complete inhibition
Liver toxicity
Synaptic plasticity impairment from off-target effects on NRG1

New Approaches:

Partial inhibition rather than complete blockade
Substrate-specific inhibitors
Antibody-based therapies
Gene therapy with ASOs[@jacobson2022]

Down Syndrome

BACE1 activity is elevated in Down syndrome due to chromosome 21 trisomy:

APP gene is on chromosome 21
Increased APP leads to increased BACE1 processing
Early-onset Aβ pathology in Down syndrome

Schizophrenia

BACE1 processing of NRG1 may affect neurodevelopment:

Altered BACE1-NRG1 signaling in schizophrenia
Potential developmental role in myelination
May affect GABAergic signaling

BACE1 in Neuroinflammation

Microglial BACE1

BACE1 is expressed in microglia and participates in neuroinflammatory responses:

Clusterin regulation: BACE1 regulates Clusterin expression in astrocytes, enhancing Aβ clearance[@chen2023]
Cytokine modulation: BACE1 activity affects inflammatory cytokine production
Phagocytosis: May influence microglial clearance functions

Cerebrovascular BACE1

BACE1 in endothelial cells contributes to vascular dysfunction in AD[@mehta2024]:

β-processing in endothelium: Contributes to cerebrovascular dysfunction
Vascular risk factors: BACE1 links cardiovascular risk to dementia
Blood-brain barrier: May affect BBB integrity

Autoantibodies to BACE1

A recent discovery reveals autoantibodies to BACE1 may promote disease progression[@yang2024]:

Prevalence: Present in human blood
Mechanism: May block normal BACE1 function or alter its trafficking
Therapeutic implications: Could affect BACE1-targeted approaches

GABA(A) Receptor Cleavage: New Mechanism

A groundbreaking 2025 study revealed BACE1 cleaves GABA(A) receptor subunits[@zhang2025]:

Discovery

BACE1 cleaves GABA(A) receptor β subunits
This decreases inhibitory signaling
Contributes to neural hyperexcitability in AD

Implications

Explains seizure susceptibility in AD
New mechanism for BACE1 toxicity
Suggests GABA(A)-targeted therapies

Therapeutic Relevance

Partial BACE1 inhibition may preserve GABA(A) function
Combined approaches targeting both Aβ production and GABA signaling

Expression

Brain Expression

BACE1 is widely expressed in the central nervous system:

Highest expression: [Hippocampus](/brain-regions/hippocampus) (CA1-CA3 pyramidal neurons), cerebral cortex (layers II-IV), amygdala
Moderate expression: Substantia nigra pars compacta, cerebellum (Purkinje cells)
Cellular localization: Primarily in neurons, lower expression in [astrocytes](/cell-types/astrocytes) and [microglia](/cell-types/microglia)
Subcellular localization: Predominantly in Golgi apparatus, endosomes, and the plasma membrane

Single-Cell Expression

| Cell Type | Expression Level | Notes |
|-----------|-----------------|-------|
| Glutamatergic neurons | High | Primary source of BACE1 |
| GABAergic neurons | Moderate | Including interneurons |
| Oligodendrocyte precursors | Moderate | Developmental expression |
| Astrocytes | Low | Increases in disease |
| Microglia | Low | Further increases with activation |

Therapeutic Targeting

Drug Development History

| Generation | Compound | Company | Status |
|------------|----------|---------|--------|
| 1st | LY2811376 | Eli Lilly | Terminated (toxicity) |
| 1st | LY2886721 | Eli Lilly | Terminated (liver toxicity) |
| 1st | MK-8931 (verubecestat) | Merck | Terminated (cognitive decline) |
| 1st | E2609 | Eisai | Terminated |
| 2nd | JNJ-54861911 | Janssen | Terminated |
| 3rd | BACE1 ASO | Various | In development |

Challenges in BACE1 Inhibition

Mechanism-based toxicity: BACE1 cleaves essential substrates beyond APP

Narrow therapeutic window: Complete inhibition causes adverse effects

Safety margin: Preclinical models showed cognitive impairment with complete inhibition

Multiple substrates: Off-target effects on NRG1, GABA(A) receptors, and others

Alternative Approaches

Partial inhibition: Maintaining minimal BACE1 activity
Substrate-specific inhibitors: Targeting only APP cleavage
Immunotherapy: Antibodies against BACE1 or Aβ
Gene therapy: siRNA and antisense oligonucleotide approaches
Allosteric modulators: Non-competitive inhibition

Interaction Network

BACE1 participates in a network of interactions relevant to AD:

| Interactor | Interaction Type | Functional Consequence |
|-----------|------------------|----------------------|
| APP | Primary substrate | Aβ production |
| γ-secretase | Sequential cleavage | Aβ release |
| BACE2 | Homolog | Potential redundancy |
| ADAM10 | Competing protease | Non-amyloidogenic processing |
| ApoE | Lipid metabolism | Aβ clearance |
| TREM2 | Microglial signaling | Phagocytosis |

Key Publications

[Vassar R, et al., Beta-secretase cleavage of Alzheimer's amyloid precursor protein (1999)](https://pubmed.ncbi.nlm.nih.gov/10519352/)

[Sinha S, et al., Purification and cloning of amyloid precursor protein beta-secretase (1999)](https://pubmed.ncbi.nlm.nih.gov/10604053/)

[Yan R, et al., Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity (1999)](https://pubmed.ncbi.nlm.nih.gov/10604052/)

[Cai J, et al., BACE1 is the major beta-secretase for generation of Abeta peptides by neurons (2011)](https://pubmed.ncbi.nlm.nih.gov/22183159/)

[May PC, et al., Robust central reduction of amyloid-beta in humans with an orally available BACE1 inhibitor (2011)](https://pubmed.ncbi.nlm.nih.gov/21994379/)

[Evin G, et al., BACE1 inhibitors: A new generation of disease-modifying drugs (2015)](https://pubmed.ncbi.nlm.nih.gov/25160169/)

[Bolognesi ML, et al., Revisiting BACE1 inhibitors for Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30657777/)

[Jacobson LH, et al., BACE1 inhibition as a therapeutic strategy for Alzheimer's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35759197/)

[Chen X, et al., BACE1 regulates expression of Clusterin in astrocytes (2023)](https://pubmed.ncbi.nlm.nih.gov/37143090/)

[Mehta D, et al., Cerebrovascular Endothelial Dysfunction: Role of BACE1 (2024)](https://pubmed.ncbi.nlm.nih.gov/38868939/)

[Yang L, et al., Autoantibodies to BACE1 promote Abeta accumulation (2024)](https://pubmed.ncbi.nlm.nih.gov/39448400/)

[Zhang Y, et al., BACE1-dependent cleavage of GABA(A) receptor (2025)](https://pubmed.ncbi.nlm.nih.gov/40015276/)

External Links

[NCBI Gene: BACE1](https://www.ncbi.nlm.nih.gov/gene/23626)
[UniProt: Q15118](https://www.uniprot.org/uniprot/Q15118)
[Ensembl: ENSG00000186318](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000186318)
[OMIM: 604252](https://omim.org/entry/604252)
[AlphaFold Structure](https://alphafold.ebi.ac.uk/entry/Q15118)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Palmitoylation-Targeted BACE1 Trafficking Disruptors](/hypothesis/h-441b25ba) — <span style="color:#ff8a65;font-weight:600">0.39</span> · Target: BACE1

Pathway Diagram

The following diagram shows the key molecular relationships involving BACE1 (Beta-Secretase 1) discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

BACE1

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-bace1
kg_node_id	BACE1
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-1836617e1b93
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-bace1'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

60

Outgoing

84

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

BACE1 (Beta-Secretase 1)

BACE1 (Beta-Secretase 1)

Introduction

Pathway / Mechanism Diagram

BACE1 (Beta-Secretase 1)

Introduction

Pathway / Mechanism Diagram

Overview

Discovery and History

Molecular Biology of BACE1

Protein Structure

Catalytic Mechanism

Function

Normal Physiological Functions

Role in Alzheimer's Disease Pathogenesis

Disease Associations

Alzheimer's Disease

Down Syndrome

Schizophrenia

BACE1 in Neuroinflammation

Microglial BACE1

Cerebrovascular BACE1

Autoantibodies to BACE1

GABA(A) Receptor Cleavage: New Mechanism

Discovery

Implications

Therapeutic Relevance

Expression

Brain Expression

Single-Cell Expression

Therapeutic Targeting

Drug Development History

Challenges in BACE1 Inhibition

Alternative Approaches

Interaction Network

Key Publications

See Also

External Links

Related Hypotheses

Pathway Diagram

💬 Discussion